Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Journal of Urology

• Publication date

  1990-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(17)39543-5PMID 2388319
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.

  1990cited by this paper
• Urindiagnostik oberflächlicher Harnblasentumoren durch Zytologie, Immunzytologie und Flowzytometrie

  1988cited by this paper
• An overview of intravesical therapy for superficial bladder tumors.

  1987cited by this paper
• Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells.

  1987cited by this paper
• Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology.

  1987cited by this paper
• Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.

  1984cited by this paper
• Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

  1982cited by this paper
• The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading.

  1978cited by this paper
• Changes in grade and stage of recurrent bladder tumors.

  1977cited by this paper
• Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.

  1976cited by this paper
• The association of urothelial atypism with neoplasia: its importance in treatment and prognosis.

  1973cited by this paper

• Immunocytology in the assessment of patients with painless gross haematuria

  2007cites this paper
• Non-invasive methods of bladder cancer detection

  2004cites this paper
• The Early Detection and Diagnosis of Bladder Cancer: A Critical Review of the Options

  2001cites this paper
• Diagnosis of Bladder Cancer with Urinary Cytology, Immunocytology and DNA-Image-Cytometry1

  2001cites this paper
• Urinary markers of malignancy.

  2000cites this paper
• Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors.

  1999cites this paper
• Use of Monoclonal Antibodies for the Diagnosis and Treatment of Bladder Cancer

  1999cites this paper
• Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder.

  1998cites this paper
• Urine cytology, tumour markers and bladder cancer.

  1998cites this paper
• Der Wert immunhistochemischer Marker (PCNA, K-67, 486 p und p53) in der Abschätzung des Rezidivrisikos oberflächlicher Blasenkarzinome

  1997cites this paper
• Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder.

  1997cites this paper
• Diagnostik der malignen Tumore der Harnblase

  1997cites this paper
• Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?

  1997cites this paper
• Klinische Erfahrungen mit der Immunzytologie mit dem monoklonalen Antikörper 486 P (Medaquic®) beim Urothelkarzinom der Blase

  1997cites this paper
• Filter immunocytology: methodologic evaluation of a new assay for the diagnosis of urothelial cancer.

  1996cites this paper
• Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study.

  1995cites this paper
• Urothelial neoplasms and tumoral markers

  1995cites this paper
• Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.

  1995cites this paper
• Quantitative Immunzytologie (Quic) mit dem monoklonalen Antikörper (mAk) 486p 3/12: Klinische Anwendung

  1995cites this paper
• [The value of urine phosphohexose isomerase activity in comparison with urine cytology. First diagnosis and tumor after-care in patients with cancer of the urinary bladder].

  1994cites this paper
• The use of monoclonal antibodies for the diagnosis and therapy of bladder cancer.

  1993cites this paper
• Urinary Cytology

  1993cites this paper
• Quantitative Immunocytology with Monoclonal Antibody (MAB) 486 p 3/12: Clinical Application

  1993cites this paper
• [What is the value of urine cytology in after-care of patients with urothelial cancers?].

  1992cites this paper
• Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder.

  1992cites this paper
• Adjuvant intravesicular pharmacotherapy for superficial bladder cancer.

  1991cites this paper
• [TNM-oriented therapy planning in bladder cancer].

  1991cites this paper
• Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.

  1991cites this paper
• Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.

  1991cites this paper
• Monoclonal antibodies in bladder cancer cytology

  1991cites this paper
• Immunzytologie bei Urotheltumoren

  1991cites this paper
• Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma.

  1991cites this paper
• Tumoren der ableitenden Harnwege

  1989cites this paper